ABSTRACT
<p><b>INTRODUCTION</b>Atopic dermatitis is a common, chronic pruritic condition affecting both children and adults, which has a negative impact on the quality of life. These guidelines were developed by an expert workgroup appointed by the Dermatological Society of Singapore, to provide doctors with information to assist in the management of their patients with atopic dermatitis. The workgroup members are experienced dermatologists with interest and expertise in eczemas.</p><p><b>MATERIALS AND METHODS</b>Workgroup members arrived at a consensus on the topics to be included. Relevant studies from the literature were assessed for best evidence, supplemented by the collective experience of the workgroup.</p><p><b>RESULTS</b>For mild atopic dermatitis, emollients, mild potency topical steroids and topical calcineurin inhibitors are recommended. For moderate-to-severe atopic dermatitis, the use of emollients, moderate-to-potent topical steroids, topical calcineurin inhibitors, wet dressings, antimicrobials for secondary skin infection, phototherapy, and systemic therapy (e.g. prednisolone, cyclosporine, azathioprine or methotrexate) may be warranted. Patients with moderate-to-severe atopic dermatitis should be managed in conjunction with a dermatologist.</p><p><b>CONCLUSION</b>Good outcomes can be achieved with an individualised therapeutic approach combined with adequate patient and parental education.</p>
Subject(s)
Humans , Administration, Cutaneous , Adrenal Cortex Hormones , Therapeutic Uses , Anti-Bacterial Agents , Therapeutic Uses , Azathioprine , Therapeutic Uses , Calcineurin Inhibitors , Therapeutic Uses , Coinfection , Drug Therapy , Cyclosporine , Therapeutic Uses , Dermatitis, Atopic , Allergy and Immunology , Therapeutics , Dermatology , Disease Management , Emollients , Therapeutic Uses , Food Hypersensitivity , Allergy and Immunology , Immunosuppressive Agents , Therapeutic Uses , Methotrexate , Therapeutic Uses , Patient Education as Topic , Phototherapy , Practice Guidelines as Topic , Referral and Consultation , Severity of Illness Index , SingaporeABSTRACT
<p><b>INTRODUCTION</b>This study aimed to assess the frequency of anxiety and depression in a cohort of adult patients with atopic dermatitis (AD) in a tertiary dermatological centre, using the Hospital Anxiety and Depression Scale (HADS). We looked for any correlation between anxiety and depression with skin disease severity.</p><p><b>MATERIALS AND METHODS</b>Patients with AD were recruited from the National Skin Centre, Singapore, from 2008 to 2009 for a prospective cross-sectional study. The scoring atopic dermatitis (SCORAD) grade was determined and the HADS was administered via interviews.</p><p><b>RESULTS</b>A total of 100 patients (78 males, 22 females) were enrolled (92% Chinese, 4% Malays and 4% Indians). Their average age was 25.7 years. Sixty-five percent used topical steroids, 14% had previously taken oral prednisolone for the control of disease flares, and 20% were on concurrent systemic therapy. The mean SCORAD was 55.0, with 99% of patients having moderate or severe AD. The mean HADS anxiety score was 7.2 and the mean depression score was 5.0. The level of anxiety correlated well with that of depression (Spearman's rank correlation coefficient, ρ = 0.59,<0.05); 18% were considered as cases of anxiety and 5% as cases of depression. These patients also had higher SCORAD values compared to other patients with lower scores for anxiety or depression (<0.05). Linear regression demonstrated a statistically significant positive relationship between anxiety and depression scores, and SCORAD scores.</p><p><b>CONCLUSION</b>Our study identified, by means of the HADS, the frequency of anxiety and depression amongst a cohort of Singaporean patients with AD. More severe skin disease correlated to greater psychological burden. The HADS is a useful screening tool that can constitute part of the overall holistic management of patients with AD so as to improve patient care.</p>